title: Maximizing the clinical utility of antimüllerian hormone testing in women's health.
abstract: OBJECTIVE
  To provide an update on the latest clinical applications of serum antimüllerian hormone (AMH) testing with practical approaches to mitigate the impact of significant variability in AMH results.
  
  
  RESULTS
  Recent studies continue to demonstrate that AMH is the best single serum test for ovarian response management with, at most, a weak-to-moderate age-independent association with live-birth rate and time to conception. Data confirm serum AMH levels improve menopause prediction, monitoring of ovarian damage, and identification of women at risk for several ovary-related disorders such as polycystic ovary syndrome and premature or primary ovarian insufficiency. However, it is now recognized that serum AMH results can have dramatic variability due to common, biologic fluctuations within some individuals, use of hormonal contraceptives or other medications, certain surgical procedures, specimen treatment, assay changes, and laboratory calibration differences. Practical guidelines are provided to minimize the impact of variability in AMH results and maximize the accuracy of clinical decision-making.
  
  
  CONCLUSIONS
  AMH is an ovarian biomarker of central importance which improves the clinical management of women's health. However, with the simultaneous rapid expansion of AMH clinical applications and recognition of variability in AMH results, consensus regarding the clinical cutpoints is increasingly difficult. Therefore, a careful approach to AMH measurement and interpretation in clinical care is essential.
authors: aClinical Research Division, ReproSource, Inc, Woburn, Massachusetts bDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California, USA.
authors: Benjamin
authors: B
authors: Leader
authors: Valerie L
authors: VL
authors: Baker
mesh_terms: D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D003661:Decision Support Techniques; D005260:Female; D006801:Humans; D008593:Menopause / Q000097:blood*; D010049:Ovarian Diseases / Q000097:blood*; D010062:Ovulation Induction / Q000379:methods*; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D016387:Women's Health
chemical_list: D015415:Biomarkers; D054304:Anti-Mullerian Hormone